Introduction {#Sec1}
============

Ever since the landmark observations of Constantin von Economo and Rene Cruchet in 1917 and subsequent publications on encephalitis lethargica, viral infections of the central nervous system (CNS) have been of great interest to neurology and neurovirology to study diseases with long-term neurological and psychiatric symptoms of unknown aetiology. Great progress has been made ever since and new CNS diseases such as subacute sclerosing panencephalitis (SSPE) or progressive multifocal leucoencephalopathy (PML) have been linked to specific virus infections. Also the group of coronaviruses which are widespread in nature, infecting animal and men and causing a variety of acute, subacute and chronic diseases, have been studied with respect to CNS involvement. It is, therefore, not surprising that in the corona virus disease 2019 (COVID-19) pandemic, CNS involvement was noted.

In the current COVID-19 pandemic, the respiratory tract is a major target of infection but some reports are showing also clinical involvement of the CNS. It is, therefore, important that not only clinical data of neurological deficits are collected but also studies are carried out to look for acute or late CNS changes with or without virus presence.

Early pathology of SARS-CoV-2 infection {#Sec2}
---------------------------------------

Fever, cough, sore throat and dyspnea are early and rather unspecific symptoms of coronavirus infections and even before its molecular detection. Pharyngodynia, nasal congestion, rhinorrhoea, smell and taste dysfunctions have been recently described as major symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Lovato and de Felippis [@CR91]; Krajewska et al. [@CR80]; Vetter et al. [@CR142]; Yan et al. [@CR152]; Table [1](#Tab1){ref-type="table"}).Table 1Early symptoms of SARS-CoV-2 infectionSymptomologyIn % of patientsReferencesFever85Lovato and de Filippis ([@CR91])Cough68.7Lovato and de Filippis ([@CR91]), Krajewska et al. ([@CR80])Sore throatKrajewska et al. ([@CR80])DyspneaKrajewska et al. ([@CR80])Pharyngodynya12.4Lovato and de Filippis ([@CR91]), Krajewska et al. ([@CR80])Nasal congestion3.7Lovato and de Filippis ([@CR91]), Krajewska et al. ([@CR80])RhinorrheaKrajewska et al. ([@CR80])Smell dysfunction68; up to 53; 98; 85,6Yan et al. ([@CR152]), Vetter et al. ([@CR142]), Moein et al. ([@CR100]), Lechien et al. ([@CR83])Anosmia (58% of *n* = 60)25Moein et al. ([@CR100])Microsmia33Moein et al. ([@CR100])Moderate microsmia27Moein et al. ([@CR100])Mild microsmia13Moein et al. ([@CR100])Normosmia2Moein et al. ([@CR100])Smell and taste dysfunction39.2Beltran-Corbellini et al. (2020), Xydakis et al. ([@CR151]), Roe ([@CR120])Loss of taste71Yan et al. ([@CR152])Gustative disorders88Lechien et al. ([@CR83])Gastrointestinal symptoms2--40Vetter et al. ([@CR142])Overall rate of conjunctivitis1.1Loffredo et al. ([@CR89])Conjunctivitis in severe cases3Loffredo et al. ([@CR89])Conjunctivitis in non-severe cases0.7Loffredo et al. ([@CR89])Conjunctival symptomsUp to 32Wu et al. ([@CR150])Fatigue39.4Lovato and de Filippis ([@CR91])Dizziness2--40Vetter et al. ([@CR142])Comorbidities Hypertension17--58Lovato and de Filippis ([@CR91]), Li et al. ([@CR86], [@CR87]), Zheng et al. ([@CR156]), Wang et al. ([@CR144]) Diabetes3.8; 9.7Lovato and de Filippis ([@CR91]), Li et al. ([@CR86], [@CR87]) Coronary heart disease3--25Lovato and de Filippis ([@CR91]), Zheng et al. ([@CR156]), Wang et al. ([@CR144]) Cardiac injury8--12Bansal ([@CR6]) Wang et al. ([@CR144]) Arrhythmias44Zheng et al. ([@CR156]), Wang et al. ([@CR144])Mortality data Ischaemic stroke74Varatharaj et al. ([@CR141]) Hypertension35Zheng et al. ([@CR156]) Coronary heart disease17Zheng et al. ([@CR156]) Venous thromboembolism58Wichmann et al. ([@CR149])"Percentage of patients" is mentioned in only a few publications, while there are a number of reports mentioning symptoms appearing in SARS-CoV-2 patients

Elderly patients and especially those with comorbidities, including obesity, type 2 diabetes, hypertension and coronary heart disease, are at risk for increased severity of COVID-19 pathology and mortality (Butler and Barrientos [@CR19]; Naughton et al. [@CR107]). Indeed, when comparing patients with non-severe infection to those with severe infection, the latter were older and had more such underlying disorders. In addition, patients with more severe infections could show neurological manifestations, such as acute cerebrovascular diseases, impaired consciousness and skeletal muscle injury (Mao et al. [@CR94]; Varatharaj et al. [@CR141]).

Only a few publications and sometimes only case reports report on autopsy studies of patients dying from COVID-19 infection (Solomon et al. [@CR132]). Weyhern et al. ([@CR143]) report the findings of six autopsies. Besides viral pneumonia, a pronounced CNS involvement with pan-encephalitis, meningitis and brain stem neuronal cell damage was a key event in all cases. CNS haemorrhage was fatal in patients younger than the age of 65 (Weyhern et al. [@CR143]). In 125 patients with complete datasets, 62% presented with a cerebrovascular event, including ischaemic stroke, intracerebral haemorrhage and one CNS vasculitis. 31% presented with altered mental status, including unspecific encephalopathy, encephalitis, neuropsychiatric disorders, psychosis, dementia-like neurocognitive syndrome and affective disorders (Varatharaj et al. [@CR141]). Encephalopathies, inflammatory CNS syndromes, ischaemic strokes and peripheral neurological disorders have been reported by Paterson et al. ([@CR115]). Autopsy studies of 18 consecutive patients with SARS-CoV-2 infection who died within 32 days after the onset of symptoms showed only hypoxic changes and did not show encephalitis. In a case report, an autopsy by Reichard et al. ([@CR119]) revealed a range of neuropathological lesions with features resembling both vascular and demyelinating etiologies.

Neurological disorders may be caused by COVID-19 due to direct infection of the brain and/or via strong activation of the immune system (Rossmann [@CR124]; Butowt and Bilinska [@CR20]) (Table [2](#Tab2){ref-type="table"}).Table 2Early neurological/psychiatric symptoms of patients with coronavirus/SARS-CoV-2SymptomologyIn % of patientsReferencesNeurological symptoms36.4--84Mao et al. ([@CR94]), Rossmann ([@CR124]), Vetter et al. ([@CR142]), Bohmwald et al. ([@CR10]), Arbour et al. ([@CR5]), Burks et al. ([@CR18]), Hung et al. ([@CR60]), Lau et al. ([@CR82]), Yeh et al. ([@CR155]), Li et al. ([@CR86], [@CR87]), Poyiadji et al. ([@CR117]), Roe ([@CR120]), Helms et al. ([@CR57])Encephalopathies/encephalitis18--23Varatharaj et al. ([@CR141]), Paterson et al. ([@CR115]), Weyhern et al. ([@CR143])Impaired consciousness15--34Mao et al. ([@CR94]), Rossmann ([@CR124]), Rogers et al. ([@CR121]), Vetter et al. ([@CR142]), Bohmwald et al. ([@CR10]), Arbour et al. ([@CR5]), Burks et al. ([@CR18]), Hung et al. ([@CR60]), Lau et al. ([@CR82]), Yeh et al. ([@CR155]), Li et al. ([@CR86], [@CR87]), Poyiadji et al. ([@CR117]), Saad et al. ([@CR126]), Pinzon et al. ([@CR116]), Varatharaj et al. ([@CR141])Confusion18--65Saad et al. ([@CR126]), Helms et al. ([@CR57]), Rogers et al. ([@CR121])Cerebrovascular diseases5.7--8.5Mao et al. ([@CR94]), Rossmann ([@CR124]), Vetter et al. ([@CR142]), Bohmwald et al. ([@CR10]), Arbour et al. ([@CR5]), Burks et al. ([@CR18]), Hung et al. ([@CR60]), Lau et al. ([@CR82]), Yeh et al. ([@CR155]), Li et al. ([@CR86], [@CR87]), Poyiadji et al. ([@CR117]), Pinzon et al. ([@CR116]), Varatharaj et al. ([@CR141])StrokeUp to 74Hess et al. ([@CR58]), Varatharaj et al. ([@CR141]), Paterson et al. ([@CR115])Skeletal muscle injury19.3Mao et al. ([@CR94]), Rossmann ([@CR124]), Vetter et al. ([@CR142]),Bohmwald et al. ([@CR10]), Arbour et al. ([@CR5]), Burks et al. ([@CR18]), Hung et al. ([@CR60]), Lau et al. ([@CR82]), Yeh et al. ([@CR155]), Li et al. ([@CR86], [@CR87]), Poyladji et al. ([@CR117]), Schoser et al ([@CR129])Myalgia13.4--71Pinzon et al. ([@CR116]), Saad et al. ([@CR126])Guillain--Barré syndromeVetter et al. ([@CR142]), Paterson et al. ([@CR115])Seizures8.6Saad et al. ([@CR126])Altered mental state31.0Varatharaj et al. ([@CR141])Acute illness Depression32.6Rogers et al. ([@CR121]) Anxiety35.7Rogers et al. ([@CR121]) Insomnia41.9Rogers et al. ([@CR121]) Psychosis0.7Rogers et al. ([@CR121])Post-illness PTSD (Posttraumatic stress disorder)32.2Rogers et al. ([@CR121]) Depression14.9Rogers et al. ([@CR121]) Anxiety disorders14.8Rogers et al. ([@CR121]) Return to work at follow-up time of 35.3 month76.9Rogers et al. ([@CR121]) Agitation69Rogers et al. ([@CR121])"Percentage of patients" is mentioned in only a few publications, while there are a number of reports mentioning symptoms appearing in SARS-CoV-2 patients

Viruses seem to enter the brain via distinct routes either by haematogenous dissemination or neuronal retrograde transport (Desforges et al. [@CR29]; Vetter et al. [@CR142]; Bohmwald et al. [@CR10]). It is assumed that SARS-CoV-2 spreads from peripheral organs, like the gastrointestinal tract, the lung, nose, other organs to the brain. Enhanced binding of SARS-CoV-2 to the nasal cavity olfactory epithelium has been suggested as primary target, as the olfactory epithelium lining blood vessels express two host receptors, ACE-2 and TMPRSS2 proteases, which facilitate virus binding, replication and accumulation (Butowt and Bilinska [@CR20]; Sungnak et al. [@CR136]). Indeed, the infection of the olfactorial epithelium seems to be responsible for olfactory dysfunction and loss of smell in patients with COVID-19 (Butowt and Bilinska [@CR20]; Sungnak et al. [@CR136]). ACE-2 may be related to both respiratory and myocardial injury, because ACE-2 is widely expressed like in the lungs and the cardiovascular system as pointed out by several authors. It is regarded that ACE-2 is a potential risk factor for both respiratory and cardiac failures in patients with COVID-19 (Long et al [@CR90]; Zheng et al. [@CR156]; Cure and Cumhur Cure [@CR26]; Hess et al. [@CR58]; Yang et al. [@CR154]; Bonow et al. [@CR13]; Driggin et al. [@CR37]; Wang et al. [@CR144]).

Spreading from the respiratory tract to the brain is suggested to be based on (1) virus transport to pass from the respiratory tract to the blood and then across the blood--brain barrier into the brain (Rossman [@CR124]; Butowt and Bilinska [@CR20]; Bohmwald et al. [@CR10]) by an transendothelial mechanism by infection of endothelial cells or via destabilisation of tight junctions by inflammatory processes, as well as (2) via infection of olfactory receptor neurons, (3) via diffusion through channels formed by olfactory ensheathing cells (van Riel et al. [@CR140]; Bohmwald et al. [@CR10]) and (4) inflammatory processes affecting the vagus nerve (Amor et al. [@CR501]). Transsynaptic transport and microfusion may occur and cause damage from infection of nerve cells per se and/or immune response (van Riel et al. [@CR140]).

Of special interest is that axons projecting from the olfactory system to the brain lack protection by the blood--brain barrier (BBB) (Broadwell and Jacobowitz [@CR17]) which allows spreading of the virus from the olfactory system to the CNS in rather short time. Experimental studies in mice with HCoV-OC43 infection showed, that neuroinvasion could be demonstrated in the olfactory bulb area after 3 days. Already at 7 days post-infection neuroinvasion of the hippocampus was evident and motor symptoms developed with progressive severity until death of the infected mice at about 20 days post-infection (Jacomy and Talbot [@CR62]; Jacomy et al. [@CR63]).

Of interest are multiexperiment matrix (MEM) data showing a coexpression link of ACE-2 and aromatic aminoacid-decarboxylase (DDC), the enzyme responsible for the synthesis of dopamine and finally noradrenaline and adrenaline from L-DOPA and serotonin from 5-hydroxytryptophan. As SARS-CoV including SARS-CoV-2 down-regulates ACE-2, this might change both the activities of the catecholamine as well as the serotonin pathways (Nataf [@CR106]). ACE-2 knockout mice generated substantially low levels of serotonin (Klempin et al. [@CR70]). These data demonstrate that involvement of neurotransmitter action and pathology is of importance and should be considered in more detail.

Smell is significantly affected in SARS-CoV-2 infected patients which may be the result of virus induced pathology of olfactory sensory neurons in the olfactory epithelium. The olfactory bulb is an important relay as it transforms signals from the olfactory sensory neurons to other parts of the olfactory system including the anterior olfactory nucleus, the olfactory tubercle, amygdala, piriform cortex and entorhinal cortex. Neurotransmitters, as acetylcholine and biogenic amines are involved in transmitting odorant perception (Rothermel et al. [@CR125]; Kapoor et al. [@CR500]; Shea et al. [@CR131]). Taste dysfunctions have been reported in patients suffering from COVID-19 infection (Xydakis et al. [@CR151]; Spinato et al. [@CR134]; Bousquet et al. [@CR14]; Beltran-Corbellini et al. [@CR8]; Gautier and Ravussin [@CR49]; Cecarelli et al. [@CR22]; Lechien et al. [@CR83]; Moein et al. [@CR100]; Sungnak et al. [@CR136]) (Table [1](#Tab1){ref-type="table"}). It has been suggested, that virus attacks the cranial nerves related to smell or the muscosal tissue surrounding these nerves. Inflammatory processes induced by viral infection are of major pathological interest in this regard (Huber [@CR59]).

With regard to coronavirus infection and especially SARS-CoV-2 of the brain, it may be of particular interest to consider infection of both the brain respiratory centre located in the medulla--pons areas and the medullary cardiovascular centres. Viral infection of those centres, which are responsible for generating and maintaining rhythms of respiration and cardiovascular activity, may disturb and even disrupt the underlying homeostasis with environmental stimuli. Disturbance or even disruptions of those pathways are risk factors which may lead and contribute to the severeness of the disease process of COVID-19 patients (Gandhi et al. [@CR48]; Lucchese and Flöel [@CR92]). Cardiac dysfunctions have been observed in patients with severe viral infection and patients with comorbidities like respiratory disorders, diabetes type II, obesity, hypertension, coronary heart disease, myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias and venous thromboembolic events (Li et al. [@CR87]; Bansal [@CR6]; Long et al. [@CR90]; Zheng et al. [@CR156]) (Table [1](#Tab1){ref-type="table"}) do have additional risk factors for the outcome of the disease process.

Recent clinical evidence shows that SARS-CoV-2 induces neuromuscular symptoms (Schoser et al. [@CR129]) with muscle pain and weakness and fatigue. In these patients, 11% revealed an increase of creatinkinase presenting with muscle weakness. Creatinkinase increased significantly with clinical severity from 22.4% in non-complicated patients to 71% of critically ill patients (Schoser et al. [@CR129]) (Table [2](#Tab2){ref-type="table"}).

Brain pathology of coronavirus infection in experiments in animals {#Sec3}
------------------------------------------------------------------

The neurotropism of certain animal coronaviruses has lead in the past to experimental studies in mice and rats to investigate the conditions leading to CNS damage using the mouse hepatitis coronavirus strain JHM (Nagashima et al. [@CR103], [@CR104]).

Three types of diseases were observed: (1) acute panencephalitis with demyelinating foci and affection of oligodendroglial cells and neurons, (2) subacute demyelinating encephalomyelitis three weeks after virus infection of new-born and weanling rats, which in about 35% developed paralysis. Demyelination was observed predominantly in the white matter of brainstem, pons, optic nerve and spinal cord. Axons and neurons were well preserved whereas virus was only detectable in oligodendroglial cells, (3) chronic progressive paralysis in 5% of infected animals 6--8 months later (Weiner [@CR148]; Nagashima et al. [@CR103], [@CR104]). Of interest is the notion, that remyelination for both, peripheral and central nervous system could be observed in clinically silent animals (Nagashima et al. [@CR105]). In both infected mice and rats, infectious virus could be isolated from brain tissue during the acute or subacute stage of encephalitis. Thereafter, infectious virus disappeared but viral antigen persisted (Sörensen and Dales [@CR133]).

More recent animal studies using mice transgenic for the SARS-CoV receptor ACE-2 demonstrated that viral brain infection covered all brain regions time dependently and complete after 4 days. Neurons were highly susceptible for SARS-CoV and prevention of severe murine disease could be reached only by absence of the host cell receptor (Netland et al. [@CR108]). As neither apoptosis or necrosis, nor inflammation could be verified in these studies, the authors speculated, that non-inflammatory processes like autophagy may be involved in the neuronal loss in SARS-CoV-infected K18-h ACE-2 mice without encephalitis (Netland et al. [@CR108]). On the basis of findings in animal experiments, the question arises if COVID-19 patients with CNS infection could develop later CNS degenerative disorders as a consequence of an infection of specific cell populations.

Implications for neurodegenerative disorders {#Sec4}
============================================

Animal studies point to the view that glial cells and oligodendroglial cells are of particular vulnerability for coronavirus infection (Barach-Latas et al. [@CR7]). Acute and persistent infections of neural cell lines with human coronavirus OC43 and 229E confirm sensitivity of glial cells towards virus infection (Bonavia et al [@CR11]; Arbour et al [@CR3], [@CR4]). Infection of human astrocytic cell line U-373MG by the OC43 strain of human coronavirus resulted in an increase of IL-6, TNF-ɑ and MCP-1 mRNA expression and modulation of the activity of matrix metalloproteinase-2 and -9. Nitric oxide production was notable in U-373MG cells as well as in microglial cell line CHME-5, indicating that coronavirus may contribute to the pathogenesis of multiple sclerosis (Edwards et al [@CR40]). Infection by HCoV-OC43 with a single-point mutation in the spike protein led to a hind-limb paralytic disease in infected mice (Brison et al. [@CR15]). This infection resulted in glutamatergic excitotoxicity, which could be antagonized by an inhibitor of AMPA receptors, GYKI-52466, which was accompanied by improvement of clinical scores and protection of CNS from neuronal dysfunction (Brison et al. [@CR15]).

In three patients suffering from MERS-CoV T2-weighted MRI imaging showed striking changes characterized by widespread, bilateral hyperintense lesions within the white matter and subcortical areas of the frontal, temporal and parietal lobes, the basal ganglia and corpus callosum, giving raise to the possibility, that MERS-CoV may lead to long-lasting severe alterations of brain tissue (Arabi et al. [@CR2]). As described in more detail by Matias-Guiu et al. ([@CR96]), coronavirus-like particles have been identified in autopsied brain tissue (Burks et al. [@CR18]; Murray et al. [@CR102]; Stewart et al. [@CR135]; Dessau et al. [@CR30]), as well as detection of antibodies to human coronavirus (Salmi et al. [@CR127]) and CoV RNA in the CSF of patients with multiple sclerosis (Cristallo et al. [@CR25]).

Parkinsonism {#Sec5}
------------

Infectious agents associated with Parkinsonism are influenza A, HIV, measles, Japanese B encephalitis, Western equine encephalitis, tick-borne encephalitis, polyomyelitis and cytomegalovirus (Nisipeanu et al. [@CR109]). Neuromelanin of the substantia nigra pars compacta is of special interest in this regard as it (1) is an immune stimulator (Oberländer et al. [@CR110]) and (2) pigmented neurons of the SN were significantly decreased in HIV-1-infected brains (Itoh et al. [@CR61]), thus contributing to dopaminergic pathology. A viral hypothesis for Parkinson's disease has been suggested for long time, namely since the influenza A pandemia 1915--1927 with post-encephalitic Parkinsonism as fatal consequence years later (Foley [@CR46]; Lutters et al. [@CR93]; Elizan and Casal [@CR42]; Takahashi and Yamada [@CR138]; Hawkes et al. [@CR55]). Any specific viral antibodies, RNA, viral particles or inclusions could not be detected in several studies in brain tissue (Martilla et al. [@CR95]; Elizan et al. [@CR43]; Jellinger [@CR65]; McCall et al. [@CR97]; Schwartz and Elizan [@CR130]; Gamboa et al. [@CR47]). These data contrast to those reported by Mihara et al. ([@CR99]) and Rohn and Catlin ([@CR122]), who have detected immunolocalization of influenza A virus in PD brain (Rohn and Catlin [@CR122]) and isolated lesions in the bilateral SN on MRI associated with influenza A (Mihara et al [@CR99]). As summarized by Oliver et al. ([@CR112]), changes in the dopaminergic system have been observed in many studies following virus infection and encephalitis. Indeed, dopaminergic neurons are heavily involved in the HIV-1 pathology using SIVmac 251 infection in rhesus monkeys as well as in a retroviral rat model of HIV and murine leucemia virus (MULV)NT 40 infections (Koutsilieri et al. [@CR75], [@CR76], [@CR77]; [@CR78]; Czub et al. [@CR27]). Experimental long-term studies with H5N1 influenza virus in mice showed that intranasal application of H5N1 induces transient loss of dopamine in the substantia nigra pars compacta (SNpc) and basal ganglia. In addition, activated microglia and increase in cytokines could be detected suggesting, that viral infection may not be excluded as trigger for Parkinsonism (Jang et al. [@CR64]).

From this experimental approach, it is hypothesized that (1) viral infection of the substantia nigra pars compacta is at risk for the development of Parkinsonism and (2), as Parkinson's disease is common in the elderly and Parkinson's disease clinically shows compromise of the respiratory and cardiac systems,  Parkinson's disease is at risk for SARS-CoV-2 infection (Helmich and Bloem [@CR56]). Indeed, HCoV has been detected in brain tissue from Parkinson's disease (Fazzini et al. [@CR45]; Arbour et al. [@CR5]). Long-term clinical observations of patients with COVID-19 infection will show, whether SARS-CoV-2 triggers Parkinsonism and/or depression in genetically vulnerable human beings.

Psychiatric symptomology {#Sec6}
------------------------

Arbour et al. ([@CR5]) have also detected HCoV-229E- and HCoV-0C43 RT-PCR-positive results in rare cases of amyotrophic lateral sclerosis (ALS), Alzheimer disease, depression and schizophrenia. SARS-CoV long-term adverse reactions, like depression and other psychiatric symptomology have not been reported in great detail. However, there is preliminary evidence to assume that depression, fatigue and sleep disturbances are evident in post-SARS-CoV patients (Moldofsky and Patcai [@CR101]). The most recent publication by Rogers et al. ([@CR121]) gives a detailed representation of psychiatric symptoms of SARS, MERS and COVID-19 patients in the acute as well as in the post illness phases (Table [2](#Tab2){ref-type="table"}). Furthermore, it cannot be excluded that in the process of SARS-CoV-2 CNS infections, impaired consciousness occurs, which my lead to cognitive deficiencies.

Indeed, besides cerebrovascular events, altered mental status was the second most common presentation compromising encephalopathy or encephalitis and primary psychiatric diagnosis, often occurring in younger patients (Varatharaj et al. [@CR141]) (Table [2](#Tab2){ref-type="table"}).

Experimental observations in the protection of brain cell damage {#Sec7}
----------------------------------------------------------------

Since we cannot exclude the possibility that SARS-COV-2 could lead to CNS damage, it is worthwhile to discuss experimental data obtained from pharmacological basic research. Enlargement of the therapeutic armamentarium for drugs protecting from virus-induced damage is scarce and limited to human case reports, experimental approaches using disease-related animal models and in vitro studies. To mention a few ones, the following options have been proposed: therapeutic strategies related to neurotransmitter pathology are targeting ACE-2. As there are close interactions between ACE-2 and nicotinic receptors, nicotine exposure due to smoking has been predicted to enhance the risk for COVID-19 neuroinfection (Kabbani and Olds [@CR68]). Therefore, nicotine receptor antagonists may counteract the risk for SARS-CoV-2 viral brain entry and brain pathology. Even of more interest is the data showing a potentiation of SIV replication by drugs used clinically to substitute loss of dopamine in Parkinson's disease (Scheller et al [@CR128]). The conclusion of this work possibly is of interest for clinical treatment options in HIV-1 infected patients with a parkinsonism/dementia syndrome. While levodopa and inhibitors of monoamine oxidase B (MAO-I) therapy of parkinsonism is obsolete in this regard (Koutsilieri et al [@CR77], [@CR78], [@CR79]), treatment with the NMDA-receptor channel antagonists amantadine/memantine are advised from these experimental studies (Meisner et al. [@CR98]; Olney et al. [@CR114]).

Aminoadamantanes, amantadine and memantine have been used for long time in the treatment of Parkinson's disease (amantadine) and Alzheimer disease (memantine). These drugs are primarily glutamate related NMDA-receptor channel antagonists (Kornhuber et al. [@CR72], [@CR73]) and inhibit glutamatergic excitotoxicity associated with these neurodegenerative disorders. More recent studies support the antiviral potential of aminoadamantanes, including development of novel compounds (Kesel et al. [@CR69]) and treatment of virus replication (Leibowitz and Reneker [@CR84]) including HCoV-OC43 replication by memantine (Brison et al. [@CR16]). Most recently, Hasanagic and Serdarevic ([@CR54]) suggested that memantine (besides its NMDA-R channel blocking properties) through its α7-nAChR antagonism may counteract proinflammatory cytokines induced in cell cultures by HCoV-OC43. This is of special interest, because α7-nAChR is localized in lungs and in the CNS. As ACE-2 expression is mediated by stimulation of α7-nAChR nicotine (smoking!) might promote entry of SARS-CoV-2 into the respiratory epithelium.

Serotonin antagonists have been proposed too. Cinanserin (SQ10,643) has been studied in bacterially expressed 3 CL pro SARS-CoV and the related human coronavirus 229E. 5microM of cinanserin inhibited the catalytic activity by 50% (Chen et al. [@CR23]). The antiviral activity of cinanserin could be substantiated in tissue culture assays and confirmed strong inhibition of coroanvirus replication (Chen et al. [@CR23]; Yang et al. [@CR153]).

 Interestingly, a very recent screening of substances effective to inhibit SARS-COV-2 showed that the antidepressant serotonin selective reuptake inhibitor (SSRI) fluoxetine inhibited the virus at a concentration of 0.8 µg/ml (Zimniak et al [@CR157]). These studies demonstrated that cianserin and fluoxetine enter at a structural site of the virus which is important for the replication of SARS-CoV-2 and this is independent from the compounds action on the serotonergic system.

An initial "cytokine storm" induced by viral suppression of pineal melatonin has been suggested to contribute to virus-induced brain pathology (Anderson and Reiter [@CR1]). Pineal melatonin is involved in a variety of intermediary cell processes, including the activation of the tricarboxylic acid cycle, oxidative phosphorylation and ATP production, thus regulating mitochondrial and immune cell phenotype (Anderson and Reiter [@CR1]). Drug development to enhance melatonin concentration and function seems to be a useful target to reduce viral infection potential.

NOS2/NO is associated with regulation of chemokine expression and inflammation. Inhibition of NOS2/NO slows the progression of MHV-induced demyelination (Lane et al. [@CR81]). There is also a role for apoD in the regulation of inflammation and suggests that it protects from HVoV-OC43-induced encephalitis, probably through the phospholipase A2 signalling pathway (Do Carmo et al. [@CR31]). Some more recent developments are those directed to treat the acute respiratory distress syndrome (ARDS) (Dreher et al. [@CR36]), which shows inflammation due to acute hypoxemia and diffuse alveolar injury "following a triggering factor" (Santos Nasciemento et al. [@CR35]). These authors propose the development of fluorophenyl imidazole-derived molecules to treat pathologies, in which inflammation, in particular based on p38 MAPK and NFkB, plays a privotal role (Santos Nasciemento et al. [@CR35]).

These examples point to the view that research on transmitter alterations after virus infection might be suitable (1) to gain knowledge about virus induced neuronal pathology of the CNS and (2) to get new targets for developing neuron protective and restorative drugs. For coronavirus, neurochemical, molecular biological/genetic research enlightening nerval participation of coronavirus toxic affection are largely missing.

Conclusion {#Sec8}
==========

Although there is abounding description of virus-induced pathology of peripheral organs, there is lack of evidence as to the viral staging pathology of brain regions and of neuron as well as of glial affection. This, however, seems to be of importance as evidence is accumulating, that viruses and especially coronaviruses including SARS-CoV-2 infect the brain with great affinity to brain regions. Long-term pathological outcome of coronavirus-induced brain affection facilitating or even triggering brain associated disorders like neurodegenerative disorders have to be considered. Therefore, it is important to learn more about SARS-CoV-2-induced brain affection and its short- as well as its long-term consequences. As such targets for future clinical and brain coronavirus-related research and unmet needs are summarized:Human postmortem brain studies are essential to understand HCoV-induced brain pathologies (Ellul et al. [@CR44]; Glatzel [@CR50]), including neuropathology and regional human postmortem neurotransmitter analyses. Moreover, molecular biological and---genetic studies should give evidence for functional disturbances caused by coronavirus affection. Virus affection of neuromelanin containing substantia nigra and locus coeruleus as well as research on coronavirus damaged oligodendrocytes are of importance to understand the vulnerability potential for neurodegenerative disorders.Regional detection of virus footprints and RNA in postmortem brains, as well as spreading characteristics of coronaviral infection/time dependency/staging in animal studies/models and longitudinal studies are necessary to enlighten details of SARS-CoV-2 affinity to brain regions.Studies of mechanisms to explain the differences of coronaviral variations of neuropathology in mice and rat strains as well as in organoids are of importance, in particular, since the pathological outcome of coronavirus infection in various strains of rodents need an explanation (Dörries et al [@CR33], [@CR34]).Age-dependent variety (young/adult/aged) and gender specificity, regarding severity of SARS-CoV-2 neurovirulence should be studied in animal experiments to understand the great divergence of CoV infection rates.In addition, studies to the genetic and immunological background of host are regarded as important in this respect. Not much is known to characterise specificity and selectivity of various viral infection factors for resistance against viral attacks.Drug developments to protect neurons and glia from coronavirus induced pathology are of importance to protect nerve tissue from viral toxicity beside SARS-CoV-2 treatment strategies.

Answers to these questions may contribute to understand why SARS-CoV-2 affects aged and young human beings so differently. Age, reduced immunological defence, comorbidity and underlying genetic vulnerabilities are at risk for the severity of viral attack in general and SARS-CoV-2 in particular. In this respect, extensive clinical, neuropathological and molecular biologic/neurochemical postmortem studies as well as animal and in vitro studies are of utmost importance to uncover the enigma of viral infections and its disastrous pathology.

So far, we have learned that beside the respiratory tract as the main organ being infected in humans, the SARS-CoV-2 virus has the potential to spread and infect other organs as well. It has to be seen, to what longlasting deficits may develop.
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